FDA grants priority review for Boehringer’s zongertinib NDA in NSCLC
FDA has granted priority review for Boehringer Ingelheim’s zongertinib NDA for treating unresectable or metastatic NSCLC.
FDA has granted priority review for Boehringer Ingelheim’s zongertinib NDA for treating unresectable or metastatic NSCLC.
What's Your Reaction?
